The global lung cancer therapeutics market size is expected to reach around US$ 55.6 billion by 2030 from US$ 27.57 billion in 2021 and is expected to grow at an impressive double-digit rate of 8.11% from 2022 to 2030.
The study includes drivers and restraints of this market. The study provides an analysis of the global lung cancer therapeutics market for the period 2017-2030, wherein 2022 to 2030 is the forecast period and 2021 is considered as the base year.
Our Free Sample Reports Includes:
- In-depth Industry Analysis, Introduction, Overview, and COVID-19 Pandemic Outbreak.
- Impact Analysis 180+ Pages Research Report (Including latest research).
- Provide chapter-wise guidance on request 2022 Updated Regional Analysis with Graphical Representation of Trends, Size, & Share, Includes Updated List of figures and tables.
- Updated Report Includes Major Market Players with their Sales Volume, Business Strategy and Revenue Analysis by using Precedence Research methodology.
Download Free Sample Copy Here (Including TOC, List of Tables & Figures, and Chart) @ https://www.precedenceresearch.com/sample/1659
Report Scope of the Lung Cancer Therapeutics Market
| Report Coverage | Details |
| Market Size by 2030 | USD 55.6 Billion |
| Growth Rate from 2022 to 2030 | CAGR of 8.11% |
| Largest Market | North America |
| Fastest Growing Market | Asia Pacific |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
Covid-19 Impact on Lung Cancer Therapeutics Market
Covid-19 had a major impact on almost all the global industries such as construction, manufacturing, oil and gas, food and beverages, etc. The demand for lung cancer therapeutics has slowed a bit during the period owing to the regulations on social distancing and increasing focus on safety. In most of the regions, the routine lung cancer therapeutics were canceled owing to the virus phobia. Also, the healthcare professionals were deployed in the treatment of patients suffering from covid-19. However, as lung cancer therapeutics is necessary for the patient population, the market will retain it’s growth projection in a short period of time.
Research Methodology
A unique research methodology has been utilized to conduct comprehensive research on the growth of the global lung cancer therapeutics market and arrive at conclusions on the future growth prospects of the market. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the draw conclusions. Secondary sources referred to by analysts during the production of the global market report include statistics from company annual reports, SEC filings, company websites, World Bank database, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of our study on the market as a primary source.
These primary and secondary sources provided exclusive information during interviews, which serves as a validation from mattress topper industry leaders. Access to an extensive internal repository and external proprietary databases allows this report to address specific details and questions about the global lung cancer therapeutics market with accuracy. The study also uses the top-down approach to assess the numbers for each segment and the bottom-up approach to counter-validate them. This has helped to estimates the future prospects of the global market more reliable and accurate.
Why should you invest in this report?
If you are aiming to enter the global lung cancer therapeutics market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for lung cancer therapeutics are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2022-2030, so that you can plan your strategies to enter this market accordingly.
Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.
Some of the prominent players in the global lung cancer therapeutics market include:
- AstraZeneca
- BoehringerIngelheim
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- Hoffmann-La Roche
- Merck & Co
- Pfizer Inc.
- Allergan Inc.
- TevaPharmaceutical Industries Ltd.
- Abbvie, Inc.
- Johnson & Johnson
- Amgen Inc.
- Novartis AG
Market Segmentation:
By Therapy
- Radiation Therapy
- External Beam
- Internal Beam
- Systemic
- Targeted Therapy
- Bevacizumab
- Dabrafenib/Trametinib
- Erlotinib Hydrochloride
- Osimertinib
- Others
- Immunotherapy
- Durvalumab
- Nivolumab
- Atezolizumab
- Pembrolizumab
- Chemotherapy
- Others
By Lung Cancer Type
- Small Cell Lung Cancer
- Non-small Cell Lung Cancer
- Lung Carcinoid Tumor
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Type of Molecule
- Small molecules
- Biologics
By Drug Class
- Alkylating Agents
- Antimetabolites
- EGFR Inhibitors
- Mitotic Inhibitors
- Multikinase Inhibitors
- Others
Regional Analysis:
The geographical analysis of the global lung cancer therapeutics market has been done for North America, Europe, Asia-Pacific, and the Rest of the World.
The North American Market is again segmented into the US, Canada, and Mexico. Coming to the European Market, it can be segmented further into the UK, Germany, France, Italy, Spain, and the rest. Coming to the Asia-Pacific, the global lung cancer therapeutics Market is segmented into China, India, Japan, and Rest of Asia Pacific. Among others, the market is segmented into the Middle East and Africa, (GCC, North Africa, South Africa and Rest of the Middle East & Africa).
Key Questions Answered by the Report:
- What will be the size of the global lung cancer therapeutics market in 2030?
- What is the expected CAGR for the lung cancer therapeutics market between 2021 and 2030?
- Which are the top players active in this global market?
- What are the key drivers of this global market?
- How will the market situation change in the coming years?
- Which region held the highest market share in this global market?
- What are the common business tactics adopted by players?
- What is the growth outlook of the global lung cancer therapeutics market?
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Lung Cancer Therapeutics Market
5.1. COVID-19 Landscape: Lung Cancer Therapeutics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Lung Cancer Therapeutics Market, By Therapy Type
8.1. Lung Cancer Therapeutics Market, by Therapy Type, 2022-2030
8.1.1. Radiation Therapy
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Targeted Therapy
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Immunotherapy
8.1.3.1. Market Revenue and Forecast (2017-2030)
8.1.4. Chemotherapy
8.1.4.1. Market Revenue and Forecast (2017-2030)
8.1.5. Others
8.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Lung Cancer Therapeutics Market, By Lung Cancer Type
9.1. Lung Cancer Therapeutics Market, by Lung Cancer Type, 2022-2030
9.1.1. Small Cell Lung Cancer
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Non-small Cell Lung Cancer
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Lung Carcinoid Tumor
9.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Lung Cancer Therapeutics Market, By Distribution Channel Type
10.1. Lung Cancer Therapeutics Market, by Distribution Channel Type, 2022-2030
10.1.1. Hospital Pharmacies
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Retail Pharmacies
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Online Pharmacies
10.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Lung Cancer Therapeutics Market, By Type of Molecule
11.1. Lung Cancer Therapeutics Market, by Type of Molecule, 2022-2030
11.1.1. Small molecules
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Biologics
11.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global Lung Cancer Therapeutics Market, By Drug Class
12.1. Lung Cancer Therapeutics Market, by Drug Class, 2022-2030
12.1.1. Alkylating Agents
12.1.1.1. Market Revenue and Forecast (2017-2030)
12.1.2. Antimetabolites
12.1.2.1. Market Revenue and Forecast (2017-2030)
12.1.3. Multikinase Inhibitors
12.1.3.1. Market Revenue and Forecast (2017-2030)
12.1.4. Mitotic Inhibitors
12.1.4.1. Market Revenue and Forecast (2017-2030)
12.1.5. EGFR Inhibitors
12.1.5.1. Market Revenue and Forecast (2017-2030)
12.1.6. Others
12.1.6.1. Market Revenue and Forecast (2017-2030)
Chapter 13. Global Lung Cancer Therapeutics Market, Regional Estimates and Trend Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Therapy (2017-2030)
13.1.2. Market Revenue and Forecast, by Lung Cancer (2017-2030)
13.1.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.1.4. Market Revenue and Forecast, by Type of Molecule (2017-2030)
13.1.5. Market Revenue and Forecast, by Drug Class (2017-2030)
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Therapy (2017-2030)
13.1.6.2. Market Revenue and Forecast, by Lung Cancer (2017-2030)
13.1.6.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.1.6.4. Market Revenue and Forecast, by Type of Molecule (2017-2030)
13.1.7. Market Revenue and Forecast, by Drug Class (2017-2030)
13.1.8. Rest of North America
13.1.8.1. Market Revenue and Forecast, by Therapy (2017-2030)
13.1.8.2. Market Revenue and Forecast, by Lung Cancer (2017-2030)
13.1.8.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.1.8.4. Market Revenue and Forecast, by Type of Molecule (2017-2030)
13.1.8.5. Market Revenue and Forecast, by Drug Class (2017-2030)
13.2. Europe
13.2.1. Market Revenue and Forecast, by Therapy (2017-2030)
13.2.2. Market Revenue and Forecast, by Lung Cancer (2017-2030)
13.2.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.2.4. Market Revenue and Forecast, by Type of Molecule (2017-2030)
13.2.5. Market Revenue and Forecast, by Drug Class (2017-2030)
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Therapy (2017-2030)
13.2.6.2. Market Revenue and Forecast, by Lung Cancer (2017-2030)
13.2.6.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.2.7. Market Revenue and Forecast, by Type of Molecule (2017-2030)
13.2.8. Market Revenue and Forecast, by Drug Class (2017-2030)
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Therapy (2017-2030)
13.2.9.2. Market Revenue and Forecast, by Lung Cancer (2017-2030)
13.2.9.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.2.10. Market Revenue and Forecast, by Type of Molecule (2017-2030)
13.2.11. Market Revenue and Forecast, by Drug Class (2017-2030)
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Therapy (2017-2030)
13.2.12.2. Market Revenue and Forecast, by Lung Cancer (2017-2030)
13.2.12.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.2.12.4. Market Revenue and Forecast, by Type of Molecule (2017-2030)
13.2.13. Market Revenue and Forecast, by Drug Class (2017-2030)
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Therapy (2017-2030)
13.2.14.2. Market Revenue and Forecast, by Lung Cancer (2017-2030)
13.2.14.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.2.14.4. Market Revenue and Forecast, by Type of Molecule (2017-2030)
13.2.15. Market Revenue and Forecast, by Drug Class (2017-2030)
13.3. APAC
13.3.1. Market Revenue and Forecast, by Therapy (2017-2030)
13.3.2. Market Revenue and Forecast, by Lung Cancer (2017-2030)
13.3.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.3.4. Market Revenue and Forecast, by Type of Molecule (2017-2030)
13.3.5. Market Revenue and Forecast, by Drug Class (2017-2030)
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Therapy (2017-2030)
13.3.6.2. Market Revenue and Forecast, by Lung Cancer (2017-2030)
13.3.6.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.3.6.4. Market Revenue and Forecast, by Type of Molecule (2017-2030)
13.3.7. Market Revenue and Forecast, by Drug Class (2017-2030)
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Therapy (2017-2030)
13.3.8.2. Market Revenue and Forecast, by Lung Cancer (2017-2030)
13.3.8.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.3.8.4. Market Revenue and Forecast, by Type of Molecule (2017-2030)
13.3.9. Market Revenue and Forecast, by Drug Class (2017-2030)
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Therapy (2017-2030)
13.3.10.2. Market Revenue and Forecast, by Lung Cancer (2017-2030)
13.3.10.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.3.10.4. Market Revenue and Forecast, by Type of Molecule (2017-2030)
13.3.10.5. Market Revenue and Forecast, by Drug Class (2017-2030)
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Therapy (2017-2030)
13.3.11.2. Market Revenue and Forecast, by Lung Cancer (2017-2030)
13.3.11.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.3.11.4. Market Revenue and Forecast, by Type of Molecule (2017-2030)
13.3.11.5. Market Revenue and Forecast, by Drug Class (2017-2030)
13.4. MEA
13.4.1. Market Revenue and Forecast, by Therapy (2017-2030)
13.4.2. Market Revenue and Forecast, by Lung Cancer (2017-2030)
13.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.4.4. Market Revenue and Forecast, by Type of Molecule (2017-2030)
13.4.5. Market Revenue and Forecast, by Drug Class (2017-2030)
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Therapy (2017-2030)
13.4.6.2. Market Revenue and Forecast, by Lung Cancer (2017-2030)
13.4.6.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.4.6.4. Market Revenue and Forecast, by Type of Molecule (2017-2030)
13.4.7. Market Revenue and Forecast, by Drug Class (2017-2030)
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Therapy (2017-2030)
13.4.8.2. Market Revenue and Forecast, by Lung Cancer (2017-2030)
13.4.8.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.4.8.4. Market Revenue and Forecast, by Type of Molecule (2017-2030)
13.4.9. Market Revenue and Forecast, by Drug Class (2017-2030)
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Therapy (2017-2030)
13.4.10.2. Market Revenue and Forecast, by Lung Cancer (2017-2030)
13.4.10.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.4.10.4. Market Revenue and Forecast, by Type of Molecule (2017-2030)
13.4.10.5. Market Revenue and Forecast, by Drug Class (2017-2030)
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Therapy (2017-2030)
13.4.11.2. Market Revenue and Forecast, by Lung Cancer (2017-2030)
13.4.11.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.4.11.4. Market Revenue and Forecast, by Type of Molecule (2017-2030)
13.4.11.5. Market Revenue and Forecast, by Drug Class (2017-2030)
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Therapy (2017-2030)
13.5.2. Market Revenue and Forecast, by Lung Cancer (2017-2030)
13.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.5.4. Market Revenue and Forecast, by Type of Molecule (2017-2030)
13.5.5. Market Revenue and Forecast, by Drug Class (2017-2030)
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Therapy (2017-2030)
13.5.6.2. Market Revenue and Forecast, by Lung Cancer (2017-2030)
13.5.6.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.5.6.4. Market Revenue and Forecast, by Type of Molecule (2017-2030)
13.5.7. Market Revenue and Forecast, by Drug Class (2017-2030)
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Therapy (2017-2030)
13.5.8.2. Market Revenue and Forecast, by Lung Cancer (2017-2030)
13.5.8.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)
13.5.8.4. Market Revenue and Forecast, by Type of Molecule (2017-2030)
13.5.8.5. Market Revenue and Forecast, by Drug Class (2017-2030)
Chapter 14. Company Profiles
14.1. AstraZeneca
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. BoehringerIngelheim
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. Bristol-Myers Squibb Company
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Eli Lilly and Company
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Hoffmann-La Roche
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Merck & Co
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Pfizer Inc.
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Allergan Inc.
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. TevaPharmaceutical Industries Ltd.
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Abbvie, Inc.
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
14.11. Johnson & Johnson
14.11.1. Company Overview
14.11.2. Product Offerings
14.11.3. Financial Performance
14.11.4. Recent Initiatives
14.12. Amgen Inc.
14.12.1. Company Overview
14.12.2. Product Offerings
14.12.3. Financial Performance
14.12.4. Recent Initiatives
14.13. Novartis AG
14.13.1. Company Overview
14.13.2. Product Offerings
14.13.3. Financial Performance
14.13.4. Recent Initiatives
Chapter 15. Research Methodology
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
Chapter 16. Appendix
16.1. About Us
16.2. Glossary of Terms
Buy Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1659
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
0 Comments